Literature DB >> 20710011

Systemic energy homeostasis in Huntington's disease patients.

N Ahmad Aziz1, Hanno Pijl, Marijke Frölich, Marieke Snel, Trea C M Streefland, Ferdinand Roelfsema, Raymund A C Roos.   

Abstract

BACKGROUND: Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an increased number of CAG repeats in the HTT gene. Apart from neurological impairment, the disease is also accompanied by progressive weight loss, abnormalities in fat and glucose homeostasis and a higher prevalence of diabetes mellitus, the causes of which are unknown. Therefore, a detailed analysis of systemic energy homeostasis in HD patients in relation to disease characteristics was performed.
METHODS: Indirect calorimetry combined with a hyperinsulinaemic-euglycaemic clamp with stable isotopes ([6,6-2H2]-glucose and [2H5]- glycerol) was performed to assess energy expenditure and glucose and fat metabolism in nine early stage, medication free HD patients and nine age, sex and body mass index matched controls.
RESULTS: Compared with controls, fasting energy expenditure was higher in HD patients (1616 ± 72 vs 1883 ± 93 kcal/24 h, p=0.037) and increased even further after insulin stimulation (1667 ± 87 vs 2068 ± 122 kcal/24 h, p=0.016). During both basal and hyperinsulinaemic conditions, glucose and glycerol disposal rates, endogenous glucose production and hepatic insulin sensitivity were similar between HD patients and controls. In HD patients, energy expenditure increased with disease duration but not with a greater degree of motor or functional impairment. Moreover, a higher mutant CAG repeat size was associated with lower insulin sensitivity (r=-0.84, p=0.018).
CONCLUSION: These findings suggest sympathetic hyperactivity as an underlying mechanism of increased energy expenditure in HD, as well as peripheral polyglutamine length dependent interference of mutant huntingtin with insulin signalling that may become clinically relevant in carriers of mutations with large CAG repeat sizes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20710011     DOI: 10.1136/jnnp.2009.191833

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  19 in total

1.  Increased catabolic state in spinocerebellar ataxia type 1 patients.

Authors:  Anja Mähler; Jochen Steiniger; Matthias Endres; Friedemann Paul; Michael Boschmann; Sarah Doss
Journal:  Cerebellum       Date:  2014-08       Impact factor: 3.847

2.  Abnormal Weight and Body Mass Index in Children with Juvenile Huntington's Disease.

Authors:  Alexander Tereshchenko; Michael McHugh; Jessica K Lee; Pedro Gonzalez-Alegre; Kaitlin Crane; Jeffrey Dawson; Peg Nopoulos
Journal:  J Huntingtons Dis       Date:  2015

3.  Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis.

Authors:  Eva Lindauer; Luc Dupuis; Hans-Peter Müller; Heiko Neumann; Albert C Ludolph; Jan Kassubek
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

4.  A novel multiplex cell viability assay for high-throughput RNAi screening.

Authors:  Daniel F Gilbert; Gerrit Erdmann; Xian Zhang; Anja Fritzsche; Kubilay Demir; Andreas Jaedicke; Katja Muehlenberg; Erich E Wanker; Michael Boutros
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

5.  Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood.

Authors:  Anthony W S Chan; Jie Jiang; Yiju Chen; Chunxia Li; Melinda S Prucha; Yijuan Hu; Tim Chi; Sean Moran; Tayeb Rahim; Shihua Li; Xiaojiang Li; Stuart M Zola; Claudia M Testa; Hui Mao; Rosa Villalba; Yoland Smith; Xiaodong Zhang; Jocelyne Bachevalier
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

Review 6.  Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Authors:  Xin Du; Terence Y Pang
Journal:  Front Psychiatry       Date:  2015-03-09       Impact factor: 4.157

7.  HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation.

Authors:  Jeffrey B Carroll; Amy Deik; Elisa Fossale; Rory M Weston; Jolene R Guide; Jamshid Arjomand; Seung Kwak; Clary B Clish; Marcy E MacDonald
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

8.  Factors Associated with Low Body Mass Index in Huntington's Disease: A Spanish Multicenter Study of the European Huntington's Disease Registry.

Authors:  Esther Cubo; Jessica Rivadeneyra; Natividad Mariscal; Asunción Martinez; Diana Armesto; Rafael J Camara
Journal:  Mov Disord Clin Pract       Date:  2016-01-18

9.  Body Mass Index Decline Is Related to Spinocerebellar Ataxia Disease Progression.

Authors:  Alhassane Diallo; Heike Jacobi; Tanja Schmitz-Hübsch; Arron Cook; Robyn Labrum; Alexandra Durr; Alexis Brice; Perrine Charles; Cecilia Marelli; Caterina Mariotti; Lorenzo Nanetti; Marta Panzeri; Maria Rakowicz; Anna Sobanska; Anna Sulek; Ludger Schöls; Holger Hengel; Bela Melegh; Alessandro Filla; Antonella Antenora; Jon Infante; José Berciano; Bart P van de Warrenburg; Dagmar Timmann; Sylvia Boesch; Massimo Pandolfo; Jörg B Schulz; Peter Bauer; Paola Giunti; Laszlo Baliko; Michael H Parkinson; Jun-Suk Kang; Thomas Klockgether; Sophie Tezenas du Montcel
Journal:  Mov Disord Clin Pract       Date:  2017-08-11

10.  Is metabolic flexibility altered in multiple sclerosis patients?

Authors:  Anja Mähler; Jochen Steiniger; Markus Bock; Alexander U Brandt; Verena Haas; Michael Boschmann; Friedemann Paul
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.